118 related articles for article (PubMed ID: 1760523)
1. Increased level of soluble interleukin-2 receptor in sera of patients with Graves' disease.
Balázs CS
Biomed Pharmacother; 1991; 45(7):311-4. PubMed ID: 1760523
[TBL] [Abstract][Full Text] [Related]
2. Soluble interleukin-2 receptor in sera of patients with Graves' disease.
Balázs C; Farid NR
Acta Med Hung; 1991; 48(1-2):3-11. PubMed ID: 1813855
[TBL] [Abstract][Full Text] [Related]
3. Soluble interleukin-2 receptor in sera of patients with Graves' disease.
Balazs C; Farid NR
J Autoimmun; 1991 Aug; 4(4):681-8. PubMed ID: 1777014
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking.
Salvi M; Pedrazzoni M; Girasole G; Giuliani N; Minelli R; Wall JR; Roti E
Eur J Endocrinol; 2000 Aug; 143(2):197-202. PubMed ID: 10913938
[TBL] [Abstract][Full Text] [Related]
5. Soluble intercellular adhesion molecule-1 (sICAM-1) in Graves' disease.
Balázs C; Kiss E
Acta Microbiol Immunol Hung; 1994; 41(4):451-6. PubMed ID: 7866729
[TBL] [Abstract][Full Text] [Related]
6. [Fluctuations in the titers of anti-thyroid hormone and anti-thyroglobulin antibodies in 4 cases of Graves' disease during long-term treatment period].
Komaki T; Sakata S; Nakamura S; Matsuda M; Kojima N; Takuno H; Miura K
Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):627-39. PubMed ID: 2583311
[TBL] [Abstract][Full Text] [Related]
7. Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves' hyperthyroidism during antithyroid drug therapy.
Kuo SW; Huang WS; Hu CA; Liao WK; Fung TC; Wu SY
Eur J Endocrinol; 1994 Aug; 131(2):125-30. PubMed ID: 8075781
[TBL] [Abstract][Full Text] [Related]
8. In vitro suppression of anti-TSH receptor antibody by autologous anti-idiotypic antibody in patients with Graves' disease.
Balázs C; Molnár I
Acta Microbiol Immunol Hung; 1995; 42(2):163-9. PubMed ID: 7551709
[TBL] [Abstract][Full Text] [Related]
9. Serum immunoglobulin G4 levels and Graves' disease phenotype.
Martin CS; Sirbu AE; Betivoiu MA; Florea S; Barbu CG; Fica SV
Endocrine; 2017 Feb; 55(2):478-484. PubMed ID: 27819113
[TBL] [Abstract][Full Text] [Related]
10. The balance shift in Th1/Th2 related IL-12/IL-5 cytokines in Graves' disease during methimazole therapy.
Molnár I
Autoimmunity; 2007 Feb; 40(1):31-7. PubMed ID: 17364495
[TBL] [Abstract][Full Text] [Related]
11. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S
J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
[TBL] [Abstract][Full Text] [Related]
12. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
[TBL] [Abstract][Full Text] [Related]
13. Blocking-type anti-TSH receptor antibodies and relation to responsiveness to antithyroid drug therapy and remission in Graves' disease.
Tada H; Mizuta I; Takano T; Tatsumi KI; Izumi Y; Hidaka Y; Amino N
Clin Endocrinol (Oxf); 2003 Apr; 58(4):403-8. PubMed ID: 12641621
[TBL] [Abstract][Full Text] [Related]
14. Increased soluble interleukin 2 receptor levels in autoimmune thyroid disease.
Nakanishi K; Taniguchi Y; Ohta Y
Acta Endocrinol (Copenh); 1991 Sep; 125(3):253-8. PubMed ID: 1683085
[TBL] [Abstract][Full Text] [Related]
15. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
[TBL] [Abstract][Full Text] [Related]
16. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease.
Rittmaster RS; Abbott EC; Douglas R; Givner ML; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1998 Mar; 83(3):814-8. PubMed ID: 9506733
[TBL] [Abstract][Full Text] [Related]
17. Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease.
Salvi M; Girasole G; Pedrazzoni M; Passeri M; Giuliani N; Minelli R; Braverman LE; Roti E
J Clin Endocrinol Metab; 1996 Aug; 81(8):2976-9. PubMed ID: 8768861
[TBL] [Abstract][Full Text] [Related]
18. [Soluble IL-2 receptor levels in patients with Graves' ophthalmopathy].
Yang H; Wu Z; Huang X; Xie C; Yang P
Yan Ke Xue Bao; 1999 Jun; 15(2):78-80. PubMed ID: 12579704
[TBL] [Abstract][Full Text] [Related]
19. Time-dependent effect of cyclosporin-A on the TSH-receptor antibody synthesis in patients with Graves' disease.
Balázs C; Kiss E; Farid NR
Acta Med Hung; 1988; 45(1):43-52. PubMed ID: 3412862
[TBL] [Abstract][Full Text] [Related]
20. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]